Dhiraj Bhatia – författare

Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insights from cancer biology, molecular biology, biotechnology, and nanotechnology. The book explores the complex mechanisms underlying drug resistance, including alterations in key signaling pathways and the tumor microenvironment's role in cancer cell survival. It highlights advancements in drug delivery technologies, such as nanomedicine and biomimetic strategies, which enhance drug targeting and minimize off-target effects. The integration of techniques like CRISPR-Cas9 and artificial intelligence in developing next-generation therapies is also emphasized. For an academic audience, this book serves as an essential resource to foster interdisciplinary collaboration in cancer research. It equips researchers, clinicians, and industry professionals with the knowledge needed to navigate the evolving landscape of cancer therapeutics, addressing critical challenges in drug delivery and chemoresistance to improve patient outcomes.Combines knowledge from cancer biology, molecular biology, biotechnology, and nanotechnology to provide a comprehensive understanding of chemoresistance and innovative drug delivery systemsShowcases the latest advancements in drug delivery methods, including nanomedicine and biomimetic strategies, emphasizing their potential to enhance therapeutic efficacy and minimize off-target effectsPresents solutions to overcome cancer chemoresistance, equipping researchers, clinicians, and industry professionals with essential knowledge to navigate the evolving landscape of cancer therapeutics

Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insights from cancer biology, molecular biology, biotechnology, and nanotechnology. The book explores the complex mechanisms underlying drug resistance, including alterations in key signaling pathways and the tumor microenvironment's role in cancer cell survival. It highlights advancements in drug delivery technologies, such as nanomedicine and biomimetic strategies, which enhance drug targeting and minimize off-target effects. The integration of techniques like CRISPR-Cas9 and artificial intelligence in developing next-generation therapies is also emphasized. For an academic audience, this book serves as an essential resource to foster interdisciplinary collaboration in cancer research. It equips researchers, clinicians, and industry professionals with the knowledge needed to navigate the evolving landscape of cancer therapeutics, addressing critical challenges in drug delivery and chemoresistance to improve patient outcomes. - Combines knowledge from cancer biology, molecular biology, biotechnology, and nanotechnology to provide a comprehensive understanding of chemoresistance and innovative drug delivery systems- Showcases the latest advancements in drug delivery methods, including nanomedicine and biomimetic strategies, emphasizing their potential to enhance therapeutic efficacy and minimize off-target effects- Presents solutions to overcome cancer chemoresistance, equipping researchers, clinicians, and industry professionals with essential knowledge to navigate the evolving landscape of cancer therapeutics

This book offers an in-depth exploration of the latest advances in cancer therapeutics, with a strong focus on innovative drug strategies and molecular breakthroughs that are shaping the future of oncology. It explores a broad range of modern treatment approaches, including immunotherapy, targeted therapies, epigenetic modulators, and next-generation drug delivery systems.The chapters explore a wide range of topics including small molecule inhibitors, monoclonal antibodies, nanotechnology-based interventions, and emerging tools like CRISPR and AI-driven drug discovery. A key strength of the book is its integration of scientific innovation with clinical translation and regulatory considerations, offering both depth and practical relevance.By bridging the gap between research and real-world application, this book provides a forward-looking roadmap for the future of cancer care. It is an essential resource for oncologists, biomedical researchers, pharmaceutical professionals, and post-graduate students seeking a clear and up-to-date understanding of current and next-generation cancer treatments.

This book presents the latest research on combination cancer therapy and the transformative role of microRNA (miRNA) modulation in improving treatment precision and outcomes. It explores how miRNAs—key regulators of gene expression—can enhance the efficacy of chemotherapy, radiotherapy, and immunotherapy while reducing toxicity and resistance.With insights into mechanisms, delivery strategies, and clinical applications, the book bridges molecular research and clinical translation. It highlights recent progress in miRNA-based combination therapies, including advances in delivery systems, tumor targeting, and translational trials.A valuable reference for clinicians, oncologists, molecular biologists, and cancer researchers, this work provides a forward-looking perspective on harnessing miRNA therapeutics to shape the next generation of cancer treatment.